Effect of ceftriaxone on the outcome of murine pyelonephritis caused by extended-spectrum-β-lactamase-producing Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7102-7111

  Tratselas, A ^a   Simitsopoulou, M ^a   Giannakopoulou, A ^b   Dori, I ^b   Saoulidis, S ^a   Kollios, K ^a   Papaioannidou, P ^a   Pournaras, S ^c   Roilides, E ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; INTERLEUKIN 6; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; COLONY FORMING UNIT; CONTROLLED STUDY; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; FIBROBLAST; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY MEDULLA; LYMPHOCYTE; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; PYELONEPHRITIS; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENE EXPRESSION; GENETICS; KIDNEY; METABOLISM; MICROBIOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BETA-LACTAMASES; CEFTRIAXONE; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENE EXPRESSION; INTERLEUKIN-6; KIDNEY; MICE; MICE, INBRED BALB C; PYELONEPHRITIS; TREATMENT OUTCOME;

EID: 84912102854     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03974-14     Document Type: Article

References (51)

1. Giamarellou H. 2005. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs). Clin. Microbiol. Infect. 11(Suppl 4):1-16. http://dx.doi.org/10.1111/j.1469-0691.2005.01160.x.
2. Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ. Colonization and infection with extended spectrum beta-lactamaseproducing Enterobacteriaceae in high-risk patients-Review of the literature from a clinical perspective. Crit. Rev. Microbiol., in press. http://dx .doi.org/10.3109/1040841X.2013.875515.
3. st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951, table of contents. http: //dx.doi.org/10.1128/CMR.14.4.933-951.2001.
4. Kassakian SZ, Mermel LA. 2014. Changing epidemiology of infections due to extended spectrum beta-lactamase-producing bacteria. Antimicrob. Resist. Infect. Control 3:9 http://dx.doi.org/10.1186/2047-2994-3-9.
5. Zaoutis TE, Goyal M, Chu JH, Coffin SE, Bell LM, Nachamkin I, McGowan KL, Bilker WB, Lautenbach E. 2005. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 115:942-949. http://dx.doi.org/10.1542/peds.2004-1289.
6. Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, Fadda G, Cauda R. 2006. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob. Agents Chemother. 50:498-504. http://dx.doi.org/10.1128/AAC.50.2.498-504.2006.
7. Kang CI, Kim SH, Kim DM, Park WB, Lee KD, Kim HB, Oh MD, Kim EC, Choe KW. 2004. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamaseproducing Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 25: 860-867. http://dx.doi.org/10.1086/502310.
8. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. 2001. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae : risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32:1162-1171. http://dx.doi.org/10.1086 /319757.
9. Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC. 2002. Bloodstream infections by extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob. Agents Chemother. 46:1481-1491. http://dx.doi.org/10.1128/AAC.46.5.1481-1491.2002.
10. Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN. 2006. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 54:231-236. http://dx.doi.org/10.1016/j .diagmicrobio.2005.09.011.
11. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. 2005. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch. Intern. Med. 165: 1375-1380. http://dx.doi.org/10.1001/archinte.165.12.1375.
12. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. 2004. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob. Agents Chemother. 48:4574-4581. http: //dx.doi.org/10.1128/AAC.48.12.4574-4581.2004.
13. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of ex-tended-spectrum beta-lactamases. Clin. Infect. Dis. 39:31-37. http://dx .doi.org/10.1086/420816.
14. Larcombe J. 2010. Urinary tract infection in children. Am. Fam. Physician 82:1252-1256.
15. Nicolle LE. 2008. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol. Clin. North Am. 35:1-12. http: //dx.doi.org/10.1016/j.ucl.2007.09.004.
16. Chang SL, Shortliffe LD. 2006. Pediatric urinary tract infections. Pediatr. Clin. North Am. 53:379-400, vi. http://dx.doi.org/10.1016/j.pcl.2006.02 .011.
17. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, Raz R. 2004. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur. J. Clin. Microbiol. Infect. Dis. 23:163-167. http://dx.doi.org/10.1007/s10096-003 -1084-2.
18. Calbo E, Romani V, Xercavins M, Gomez L, Vidal CG, Quintana S, Vila J, Garau J. 2006. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum betalactamases. J. Antimicrob. Chemother. 57:780-783. http://dx.doi.org/10 .1093/jac/dkl035.
19. Megged O. 2014. Extended-spectrum β-lactamase-producing bacteria causing community-acquired urinary tract infections in children. Pediatr. Nephrol. 29:1583-1587. http://dx.doi.org/10.1007/s00467-014-2810-y.
20. th informational supplement. M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Hagberg L, Engberg I, Freter R, Lam J, Olling S, Svanborg Eden C. 1983. Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin. Infect. Immun. 40: 273-283.
22. Hvidberg H, Struve C, Krogfelt KA, Christensen N, Rasmussen SN, Frimodt-Moller N. 2000. Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob. Agents Chemother. 44:156-163. http://dx.doi.org/10.1128/AAC.44.1.156 -163.2000.
23. Svensson M, Irjala H, Alm P, Holmqvist B, Lundstedt AC, Svanborg C. 2005. Natural history of renal scarring in susceptible mIL-8Rh-/- mice. Kidney Int. 67:103-110. http://dx.doi.org/10.1111/j.1523-1755.2005.00060.x.
24. Johnson DE, Russell RG, Lockatell CV, Zulty JC, Warren JW, Mobley HL. 1993. Contribution of Proteus mirabilis urease to persistence, urolithiasis, and acute pyelonephritis in a mouse model of ascending urinary tract infection. Infect. Immun. 61:2748-2754.
25. Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. 2005. Epidemiology and risk factors for extended-spectrum beta-lactamaseproducing organisms: a case control study at a tertiary care center in Lebanon. Am. J. Infect. Control 33:326-332. http://dx.doi.org/10.1016/j.ajic .2005.03.009.
26. Peña C, Gudiol C, Tubau F, Saballs M, Pujol M, Dominguez MA, Calatayud L, Ariza J, Gudiol F. 2006. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin. Microbiol. Infect. 12:279-284. http://dx.doi .org/10.1111/j.1469-0691.2005.01358.x.
27. Tratselas A, Iosifidis E, Ioannidou M, Saoulidis S, Kollios K, Antachopoulos C, Sofianou D, Roilides EJ. 2011. Outcome of urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children. Pediatr. Infect. Dis. J. 30:707-710. http://dx.doi .org/10.1097/INF.0b013e31820eae6a.
28. Wang P, Hu F, Xiong Z, Ye X, Zhu D, Wang YF, Wang M. 2011. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints. J. Clin. Microbiol. 49:3127-3131. http://dx.doi.org/10.1128/JCM.00222-11.
29. Nishimoto N, Kishimoto T. 2006. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2:619-626. http://dx.doi.org/10.1038/ncprheum0338.
30. Rusconi F, Parizzi F, Garlaschi L, Assael BM, Sironi M, Ghezzi P, Mantovani A. 1991. Interleukin 6 activity in infants and children with bacterial meningitis. The Collaborative Study on Meningitis. Pediatr. Infect. Dis. J. 10:117-121. http://dx.doi.org/10.1097/00006454-199102000 -00008.
31. Waage A, Halstensen A, Shalaby R, Brandtzaeg P, Kierulf P, Espevik T. 1989. Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. J. Exp. Med. 170:1859-1867.
32. Groeneveld AB, Tacx AN, Bossink AW, van Mierlo GJ, Hack CE. 2003. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin. Immunol. 106:106-115. http://dx .doi.org/10.1016/S1521-6616(02)00025-6.
33. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC, GenIMS Investigators. 2007. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch. Intern. Med. 167:1655-1663. http://dx.doi.org/10 .1001/archinte.167.15.1655.
34. Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, Kong L, Carter M, Angus DC, GenIMS Investigators. 2008. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am. J. Respir. Crit. Care Med. 177:1242-1247. http://dx .doi.org/10.1164/rccm.200712-1777OC.
35. Gómez-Cambronero LG, Sabater L, Pereda J, Cassinello N, Camps B, Vina J, Sastre J. 2002. Role of cytokines and oxidative stress in the pathophysiology of acute pancreatitis: therapeutical implications. Curr. Drug Targets Inflamm. Allergy 1:393-403. http://dx.doi.org/10.2174 /1568010023344544.
36. Yoshii T, Magara S, Miyai D, Nishimura H, Kuroki E, Furudoi S, Komori T, Ohbayashi C. 2002. Local levels of interleukin-1beta, -4, -6 and tumor necrosis factor alpha in an experimental model of murine osteomyelitis due to Staphylococcus aureus. Cytokine 19:59-65. http://dx .doi.org/10.1006/cyto.2002.1039.
37. Davis S, Aldrich TH, Valenzuela DM, Wong VV, Furth ME, Squinto SP, Yancopoulos GD. 1991. The receptor for ciliary neurotrophic factor. Science 253:59-63. http://dx.doi.org/10.1126/science.1648265.
38. Moritz RL, Ward LD, Tu GF, Fabri LJ, Ji H, Yasukawa K, Simpson RJ. 1999. The N terminus of gp130 is critical for the formation of the highaffinity interleukin-6 receptor complex. Growth Factors 16:265-278. http: //dx.doi.org/10.3109/08977199909069145.
39. Chow D, He X, Snow AL, Rose-John S, Garcia KC. 2001. Structure of an extracellular gp130 cytokine receptor signaling complex. Science 291: 2150-2155. http://dx.doi.org/10.1126/science.1058308.
40. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC. 1988. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 232: 347-350. http://dx.doi.org/10.1016/0014-5793(88)80766-X.
41. Hedges S, Anderson P, Lidin-Janson G, de Man P, Svanborg C. 1991. Interleukin-6 response to deliberate colonization of the human urinary tract with gram-negative bacteria. Infect. Immun. 59:421-427.
42. Hedges S, Agace W, Svensson M, Sjogren AC, Ceska M, Svanborg C. 1994. Uroepithelial cells are part of a mucosal cytokine network. Infect. Immun. 62:2315-2321.
43. Agace W, Hedges S, Andersson U, Andersson J, Ceska M, Svanborg C. 1993. Selective cytokine production by epithelial cells following exposure to Escherichia coli. Infect. Immun. 61:602-609.
44. de Man P, van Kooten C, Aarden L, Engberg I, Linder H, Svanborg Eden C. 1989. Interleukin-6 induced at mucosal surfaces by gramnegative bacterial infection. Infect. Immun. 57:3383-3388.
45. Rugo HS, O'Hanley P, Bishop AG, Pearce MK, Abrams JS, Howard M, O'Garra A. 1992. Local cytokine production in a murine model of Escherichia coli pyelonephritis. J. Clin. Invest. 89:1032-1039. http://dx.doi.org /10.1172/JCI115644.
46. Hedges S, Stenqvist K, Lidin-Janson G, Martinell J, Sandberg T, Svanborg C. 1992. Comparison of urine and serum concentrations of inter-leukin-6 in women with acute pyelonephritis or asymptomatic bacteriuria. J. Infect. Dis. 166:653-656. http://dx.doi.org/10.1093/infdis/166.3 .653.
47. Sheu JN, Chen MC, Lue KH, Cheng SL, Lee IC, Chen SM, Tsay GJ. 2006. Serum and urine levels of interleukin-6 and interleukin-8 in children with acute pyelonephritis. Cytokine 36:276-282. http://dx.doi.org /10.1016/j.cyto.2007.02.006.
48. Benson M, Jodal U, Andreasson A, Karlsson A, Rydberg J, Svanborg C. 1994. Interleukin 6 response to urinary tract infection in childhood. Pediatr. Infect. Dis. J. 13:612-616. http://dx.doi.org/10.1097/00006454 -199407000-00006.
49. Jantausch BA, O'Donnell R, Wiedermann BL. 2000. Urinary interleu-kin-6 and interleukin-8 in children with urinary tract infection. Pediatr. Nephrol. 15:236-240. http://dx.doi.org/10.1007/s004670000456.
50. Rodríguez LM, Robles B, Marugan JM, Suarez A, Santos F. 2008. Urinary interleukin-6 is useful in distinguishing between upper and lower urinary tract infections. Pediatr. Nephrol. 23:429-433. http://dx.doi.org /10.1007/s00467-007-0670-4.
51. Roilides E, Papachristou F, Gioulekas E, Tsaparidou S, Karatzas N, Sotiriou J, Tsiouris J. 1999. Increased urine interleukin-6 concentrations correlate with pyelonephritic changes on 99mTc-dimercaptosuccinic acid scans in neonates with urinary tract infections. J. Infect. Dis. 180:904-907. http://dx.doi.org/10.1086/314960.